Want to see LNSR full AI Analyst Report?
LNSR Stock Chart & Stats
$11.61
-$0.54(-6.29%)
At close: 4:00 PM EST
$11.61
-$0.54(-6.29%)
Day’s Range― - ―
52-Week Range$5.06 - $13.47
Previous CloseN/A
Volume40.10K
Average Volume (3M)58.95K
Market Cap
$77.47M
Enterprise Value$65.85M
Total Cash (Recent Filing)$13.49M
Total Debt (Recent Filing)$2.57M
Price to Earnings (P/E)6.5
Beta0.96
Next Earnings
Aug 06, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.98
Shares Outstanding12,104,328
10 Day Avg. Volume51,870
30 Day Avg. Volume58,950
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)-5.34
Price to Sales (P/S)2.38
P/FCF Ratio-9.32
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue1.14
Enterprise Value/Gross Profit2.52
Enterprise Value/Ebitda1.94
Forecast
1Y Price Target
$8.50Price Target Upside-26.79% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$63.05M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue MixA very high and growing recurring-revenue mix creates more predictable top-line streams tied to procedures and consumables. That durability reduces reliance on lumpy capital system sales, supports steady margin contribution and improves revenue visibility over the next several quarters as placements ramp.
Installed Base And Procedure GrowthExpanding installed base and rising procedure volumes create a compounding recurring revenue engine: more systems and procedures drive consumable and service demand, widen adoption, and create switching costs for surgeons and centers, supporting medium-term revenue stability and upsell opportunities.
Product Roadmap And Tech DifferentiationA focused roadmap toward corneal applications and increased automation reinforces technological differentiation. Continued product innovation can expand addressable procedures, improve clinical outcomes, and strengthen competitive positioning, underpinning sustainable demand and higher-margin consumable/service revenue.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow indicate structural cash burn that constrains the company’s ability to rebuild commercial and service capacity without external funding. Weak cash generation raises liquidity and execution risk and could force dilutive financing or cutbacks over months ahead.
Ongoing Operating LossesSustained negative EBIT/EBITDA margins show that reported net income is not backed by operating profitability. Until recurring revenue converts into cash-operating earnings, the business remains reliant on non-operating gains or financing, which undermines long-term earnings quality and reinvestment capacity.
Capital-sales Volatility & International DelaySharp declines in system placements and delayed international reactivation create lumpy capital-sales cycles that limit near-term scaling. Because capital placements seed recurring revenue, multi-quarter distributor reactivation risk can slow installed-base growth and delay the expected lift to procedure-based revenues.
LENSAR News
LNSR FAQ
What was LENSAR’s price range in the past 12 months?
LENSAR lowest stock price was $5.06 and its highest was $13.47 in the past 12 months.
What is LENSAR’s market cap?
LENSAR’s market cap is $77.47M.
When is LENSAR’s upcoming earnings report date?
LENSAR’s upcoming earnings report date is Aug 06, 2026 which is in 32 days.
How were LENSAR’s earnings last quarter?
LENSAR released its earnings results on May 08, 2026. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of N/A by $1.56.
Is LENSAR overvalued?
According to Wall Street analysts LENSAR’s price is currently Overvalued.
Does LENSAR pay dividends?
LENSAR does not currently pay dividends.
What is LENSAR’s EPS estimate?
LENSAR’s EPS estimate is -0.17.
How many shares outstanding does LENSAR have?
LENSAR has 12,104,328 shares outstanding.
What happened to LENSAR’s price movement after its last earnings report?
LENSAR reported an EPS of $1.56 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 7.839%.
Which hedge fund is a major shareholder of LENSAR?
Currently, no hedge funds are holding shares in LNSR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LENSAR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (-26.79% Downside)
$8.50 (-26.79% Downside)
Blogger Sentiment
Bullish
LNSR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 172.0K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
56.49%
12-Months-Change
Fundamentals
Return on Equity
-514.92%
Trailing 12-Months
Asset Growth
-9.23%
Trailing 12-Months
Company Description
LENSAR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
LNSR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but stabilizing picture: operational fundamentals improved with durable recurring revenue growth (+9% YoY to $12.6M), installed-base expansion (+12% to ~440 systems) and rising procedure volumes (~54k). At the same time, near-term financials show weaknesses driven by a sharp decline in system revenue (~$0.8M vs $2.6M prior), a negative adjusted EBITDA (-$0.31M), modest cash ($13.5M), and one-time/non‑cash items that materially inflated GAAP net income. Management reports growing commercial momentum post-transaction (demos, distributor POs, product roadmap) but acknowledges it will take several quarters to rebuild international placements and fully restore prior growth rates. Overall, the call balances encouraging operational signs and strategic clarity against measurable near-term financial and timing challenges.View all LNSR earnings summariesLNSR Stock 12 Month Forecast
Average Price Target
$8.50
▼(-26.79% Downside)
Technical Analysis
Ownership Overview
42.73% Insiders
7.95% Mutual Funds
22.22% Other Institutional Investors
22.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---